

Acute hypertriglyceridemia and hyperglycemia related to mirtazapine: A case report

Ebru Sahan, Aise Tangiltiz

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our authors, we are providing this early version of the manuscript. The manuscript will undergo copyediting and typesetting before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Case Report

Acute hypertriglyceridemia and hyperglycemia related to mirtazapine: A case report

Ebru Sahan, Aise Tangiltiz

Department of Psychiatry, Bezmialem Foundation University Medical Faculty, Adnan Menderes Boulevard (Vatan Road), Fatih, Istanbul, Turkey

Corresponding address:

Dr. Ebru Sahan

Department of Psychiatry,

Bezmialem Foundation University Medical Faculty

Adnan Menderes Boulevard (Vatan Road),

Fatih, Istanbul

Postal code: 34093

Turkey.

Phone: +90 212 523 2288

E-mail: ebrushaan@hotmail.com

ABSTRACT

A 42-year-old woman was hospitalized with depression and was started on mirtazapine 15 mg/day. Just one week after starting mirtazapine; severe hypertriglyceridemia and hyperglycemia were detected. Although these metabolic adverse effects have been reported before, to our knowledge this is the first case of hypertriglyceridemia and hyperglycemia occurring so early -just one week- after initiation of mirtazapine. Patient's glucose and triglyceride normalized nine days after discontinuation of mirtazapine. This case emphasizes the importance of regular glucose and triglyceride measurements at baseline and then regular monitoring in patients receiving mirtazapine treatment.

KEYWORDS: adverse effects; depression; hypertriglyceridemia; hyperglycemia; mirtazapine

INTRODUCTION

Two important neurotransmitters involved in the pathophysiology of depression are serotonin and noradrenaline ^[1]. Mirtazapine is an antidepressant from the piperazineazepine group, mainly used in the treatment of depression which increases noradrenaline release by blocking alpha-2 autoreceptors ^[2]. This increase in noradrenaline levels facilitates cell firing by stimulating alpha-1 adrenoreceptors in the serotonergic cell body which stimulates the release of 5-Hydroxytryptamine (5-HT) in the synapses ^[3]. Increased serotonin in synaptic space leads to increased transmission over 5-HT₁ receptors which is probably related to antidepressant and anxiolytic effects. In addition, mirtazapine blocks 5-HT₂ and 5-HT₃ receptors and acts as a 5-HT_{1A} receptor agonist ^[4]. Mirtazapine has very weak muscarinic anticholinergic and histamine (H) antagonist properties ^[5]. Common side effects associated with mirtazapine are somnolence (54%), dizziness (7%), increased appetite (17%), weight gain (8%), increased nonfasting serum cholesterol (15%) and increased serum triglyceride (6%) levels, elevated liver transaminases (52%), constipation (13%) and dry mouth (25%). Less commonly reported side effects (<1%) include activation of mania/hypomania, asthenia, agranulocytosis and neutropenia ^[6].

The European Atherosclerosis Society/ European Federation of Clinical Chemistry and Laboratory Medicine considers non-fasting triglyceride levels of > 175 mg/dL and fasting triglyceride (TG) levels of > 150 mg/dL as upper limits while levels between 180-880 mg/dL, and above > 880 mg/dL are considered mild to moderate and severe hypertriglyceridemia, respectively ^[7]. Fasting TG levels above 150 mg/dL can be considered as elevated TG levels, which is associated with an increased risk of atherosclerosis and cardiovascular diseases. Once TG levels increase above 500 mg/dL, and particularly above 1000 mg/dL, the most important clinical outcome is markedly increased risk of pancreatitis ^[8]. Here, we present a case with an elevation of triglyceride levels three times the baseline level and elevation of glucose levels two times the baseline level, the elevation occurring within the first week of mirtazapine use.

CASE REPORT

A 42-years-old, Caucasian, married, housewife patient presented with a long-standing history of depression since the age of 25. Her history was notable for several visits to various psychiatric outpatient

clinics over the course of eleven years due to anxiety, loss of motivation, feeling upset, hopelessness, pessimism, difficulty sleeping and “feeling sleepy all day”. She had a headache starting at the age of 20 but she was examined 5 years later by a neurologist and was started on amitriptyline which she used for 6 months. The patient did not complain of the headache until the age of 31 years. Upon resumption of the depressed mood, anhedonia, early insomnia, feeling tired and being tearful all the time, she reported to the psychiatry outpatient clinic of another hospital. Although she continued her outpatient treatment, due to continuing complaints, she had been hospitalized three times and discharged with partial remissions until the age of 36 years. Despite taking several different medications including escitalopram, duloxetine, lamotrigine, sertraline, gabapentin, trazodone, venlafaxine, aripiprazole, lithium in various periods, the patient had never completely recovered. Due to the failure of symptom control in the outpatient setting, she was admitted to our hospital as an inpatient, which was overall her fourth admission. She was using metformin 1000 mg/day for her diabetes mellitus and nebivolol 5 mg/day for her hypertension. Her family history revealed major depressive disorder in her mother. She was a smoker, but she had never used alcohol or any other substance. Patient appeared to be overweight (weight:72 kg height:160 cm BMI:28,1). Her vital signs were as follows: Blood pressure: 137/63 mmHg, heart rate: 105 beats/min and body temperature: 36.7°C. Physical and neurological examinations were negative for any significant findings.

In the psychiatric examination, her mood was depressed and affect was congruent with her mood. Her appetite was normal but she had early and middle insomnia. Based on these findings, she was diagnosed with depression. Her Hamilton depression rating scale score was 18 and Beck depression inventory score was 26. On the first day of hospitalization, a complete blood count, metabolic panel, hepatic and renal function tests and urine analysis were performed, which revealed the following abnormalities: A triglyceride value of 572 mg/dL (Normal: 50-150 mg/dL), fasting glucose level of 233 mg/dL (Normal: 70-105 mg/dL), hemoglobin of 7.82 g/dL (Normal: 12.2-16.2 g/dL). Her electrocardiogram showed sinus rhythm. Hb A1c level was 5,1. Because she had impulse control problems, anxiety, early and middle insomnia, sertraline 50 mg/day, risperidone 1 mg/day and mirtazapine 15 mg/day were prescribed for her. Intravenous ferric carboxymaltose was administered for her anemia. On the seventh day of mirtazapine treatment, control blood tests revealed more than three-times increase in serum triglyceride level (from 572 to 1637 mg/dL) and about two-times increase in serum fasting glucose level (from 233 to 432 mg/dL) for which fenofibrate 267 mg/day for hypertriglyceridemia and pioglitazone 30mg/day for hyperglycemia were started. Amylase and lipase were within normal limits. After 2 days, triglyceride and glucose levels were still high (triglyceride 1670 mg/dl and glucose 413 mg/dl). Mean capillary glucose measurements were 315 mg/dl for fasting and 330 mg/dl for nonfasting. Her impulse control disorder was in remission, therefore risperidone treatment was stopped. On the 14th day of admission, her weight was 0,7 kg less than her initial weight. The urine analysis was negative for ketones or protein. Her persistently elevated triglyceride and glucose levels were suspected to be secondary to mirtazapine treatment, and therefore mirtazapine was stopped. Instead, the patient was started on trazodone for insomnia. Two days later, serum triglyceride level dropped to 878 mg/dL and serum glucose level dropped to 262 mg/dL. Her

psychiatric symptoms showed remarkable improvement and she was eventually discharged from the hospital. During her follow up examination one week later, depressive symptoms were still in remission while her triglyceride level was back to her baseline at admission (563 mg/dL on follow up, 572 mg/dL on admission) and her serum glucose level had dropped to 151 mg/dL.

Figures 1 and 2 demonstrate the change in triglyceride and glucose levels in chronological order, respectively.

DISCUSSION

The risk factors for hypertriglyceridemia include genetics, lifestyle and diet (e.g., obesity, alcohol consumption, and reduced physical activity), diseases and disorders (e.g., metabolic syndrome, insulin resistance, diabetes mellitus, renal disease), and medications (e.g., corticosteroids, estrogens, beta-blockers, thiazides, bile acid sequestrants, and immunosuppressive agents) [8].

Various antidepressants like amitriptyline, clomipramine, fluoxetine, venlafaxine, citalopram have been associated with hypertriglyceridemia and/or acute pancreatitis [9-15]. In US controlled studies, nonfasting triglyceride increases to ≥ 500 mg/dL were observed in 6% of patients treated with mirtazapine, compared to 3% for placebo and 3% for amitriptyline [6]. However, few cases have been reported about elevated serum triglyceride levels above 1000 mg/dL associated with mirtazapine in the literature. Bowers *et al* described a patient with hypertriglyceridemia induced pancreatitis for whom the suspected cause of dangerously elevated triglyceride levels was mirtazapine [16]. Chen *et al* reported a 44 year old woman with acute pancreatitis and diabetic ketoacidosis due to hypertriglyceridemia which started two months after mirtazapine treatment [17]. Similarly, Duncan *et al* reported a 75 year old male patient who developed hypertriglyceridemia followed by hyperglycemia two months after starting to use mirtazapine [18].

Our patient had concomitant diabetes mellitus and hypertriglyceridemia which might have put her to a more vulnerable position for mirtazapine induced hypertriglyceridemia and hyperglycemia although she did not gain weight or was not in diabetic ketoacidosis state.

Literature was more plentiful about mirtazapine related pancreatitis cases, suggesting the elevated serum triglyceride levels as its possible explanation. In addition to Chen *et al* and Bowers *et al*; Navarro *et al*, Sommer *et al*, Hussain and Burke, Lankisch and Werner and Stone and Puri reported acute pancreatitis cases secondary to hypertriglyceridemia in patients using mirtazapine [19-23]. However, our patient did not have the symptoms, signs or laboratory evidence of pancreatitis.

A research study observed significantly impaired glucose tolerance in acutely depressed patients compared to healthy controls. Although glucose tolerance improved under mirtazapine treatment, insulin sensitivity was still impaired and remained significantly lower in patients compared to controls [24].

Concerning 'mirtazapine' and 'hyperglycemia', Fisfalen described a patient who was on mirtazapine for appetite stimulation and who had severe hyperglycemia in addition to a 16-kg weight gain^[25]. Chen *et al* reported hyperglycemia secondary to mirtazapine therapy in a 37-year-old man^[26].

This patient had well-controlled diabetes before mirtazapine usage so we did not detect any diabetes complications. The antidiabetic drug metformin has not been related to hypertriglyceridemia, though it ameliorates obesity-associated hypertriglyceridemia in mice^[27]. The antihypertensive drug nebivolol which our patient was using has not been shown to cause significant changes in insulin sensitivity and triglyceride levels^[28,29].

The Naranjo scale, shown in Table 1, evaluates the likelihood that an adverse effect is caused by a pharmacologic agent^[30]. The Naranjo scoring system has been validated and is used in clinical practice. The probability that the adverse event was related to drug therapy was classified as Definite ≥ 9 , Probable = 5-8, Possible = 1-4, Doubtful ≤ 0 that an adverse drug reaction was caused by a drug or some other factor).

A "definite" reaction was one that (1) followed a reasonable temporal sequence after a drug or in which a toxic drug level had been established in body fluids or tissues, (2) followed a recognized response to the suspected drug, and (3) was confirmed by improvement on withdrawing the drug and reappeared on reexposure. A "probable" reaction (1) followed a reasonable temporal sequence after a drug, (2) followed a recognized response to the suspected drug, (3) was confirmed by withdrawal but not by exposure to the drug, and (4) could not be reasonably explained by the known characteristics of the patient's clinical state.

In our patient, triglyceride and glucose levels were found to be elevated only within the first week of mirtazapine treatment and were back to baseline shortly after the cessation of mirtazapine.

There are previous conclusive reports on this reaction (+1), the suspected event has appeared after the offending agent was administered (+2), adverse drug reaction improved when the offending agent was discontinued (+1), there are not alternate causes that could solely have caused the adverse drug reaction (+2). Naranjo adverse reaction scale score was "6" which corresponds to "probable causality".

CONCLUSION

In conclusion, depending on the possible association of mirtazapine and hypertriglyceridemia, serum glucose and triglyceride levels should be measured before and shortly after starting mirtazapine treatment to ensure patient safety especially in patients who are at high risk.

ACKNOWLEDGMENT

None to declare.

We have no conflicts of interest to disclose.

Authorship criteria: (1) history taking, physical and psychiatric examination and treatment of the case; the acquisition of laboratory data and interpretation of side effects; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published.

1. Author's contribution: 1,2,3
2. Author's contribution: 1,2,3

REFERENCES

1. Uzbay T. Anksiyete ve depresyonun nörobiyolojisi. *Klinik Psikiyatri Derg* 2004; 4.
2. De Boer T, Ruigt GSF. The selective α -2 adrenoceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5-HT_{1A} mediated serotonergic neurotransmission. *CNS Drugs* 1995; 4(Suppl 1):29-33.
3. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic transmission: Acute and long-term actions of mirtazapine. *Int Clin Psychopharmacology* 1995; 10(Suppl4):11-17.
4. Palaoğlu Ö, Ayhan IH. Santral sinir sisteminin psikofarmakolojik organizasyonu. *Psikiyatri, Psikoloji, Psikofarmakoloji Dergisi* 1994; 2:11-20.
5. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety, and tolerability of mirtazapine for the treatment of patients with major depression. *Journal of Affective Disorders* 1998; 51:267–285.
6. Remeron package insert. West Orange, NJ 1996; Organon Inc.
7. Çetinkalp Ş. "Soru 1–Trigliserit nedir? Normal fizyolojideki yeri nedir?." *Türk Kardiyol Dern Ars* 2017; 45 (suppl 1):1-63.
8. Kushner PA, Cobble ME. Hypertriglyceridemia: the importance of identifying patients at risk. *Postgraduate Med* 2016; 128(8):848-858.
9. Grohmann R, Rüter E, Engel RR, Hippus H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. *Pharmacopsychiatry* 1999; 32(1):21-29.
10. Pezzilli R, Melandri R, Barakat B, Broccoli PL, Miglio F. Pancreatic involvement associated with tricyclic overdose. *Italian journal of gastroenterology and hepatology* 1998; 30(4):418-420.
11. Roberge RJ, Martin TG, Hodgman M, Benitez JG. Acute chemical pancreatitis associated with a tricyclic antidepressant (clomipramine) overdose. *J Toxicol Clin Toxicol* 1994; 32(4):425–9.
12. Jeffries JJ, Masson J. Pancreatitis following overdose with amoxapine and procyclidine. *Can J Psychiatry* 1985; 30(7):546–7.
13. Kvande KT, Madsen S. Selective serotonin uptake inhibitors and pancreatitis. *Tidsskr Nor Laegeforen* 2001; 121(2):177–8.
14. Teitelbaum M. Severe and moderate hypertriglyceridemia secondary to citalopram and fluoxetine. *Psychosomatics* 2000; 41(5):448–9.

15. Teitelbaum M. Severe hypertriglyceridemia secondary to venlafaxine and fluoxetine. *Psychosomatics* 2001; 42(5):440–1.
- 16) Bowers RD, Valanejad SM, Holombo AA. Mirtazapine-induced pancreatitis—a case report. *Journal of pharmacy practice* 2018, 0897190018760645.
17. Chen JL, Spinowitz N, Karwa M. Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* 2003; 23(7):940-944.
18. Duncan NA, Clifford KM, Shvarts OM. Mirtazapine-Associated Hypertriglyceridemia and Hyperglycemia. *The Consultant Pharmacist®* 2015; 30(11):657-663.
19. Dávila N, Shihadeh LA, Plasencia García I. Pancreatitis asociada a mirtazapina. *Medicina Clínica* 2018; 150(5):206-206.
20. Sommer M, Dieterich A, Krause C, Rütther E, Wiltfang J. Subclinical pancreatitis related to mirtazapine—a case report. *Pharmacopsychiatry* 2001; 34(04):158-159.
21. Hussain A, Burke J. Mirtazapine associated with recurrent pancreatitis—a case report. *Journal of Psychopharmacology* 2008; 22(3):336-337.
22. Lankisch PG, Werner HM. Mirtazapine: another drug responsible for drug-induced acute pancreatitis? A letter of warning. *Pancreas* 2003; 26(2):211.
23. Stone J, Puri N. Mirtazapine Induced Pancreatitis With Associated Hypertriglyceridemia and Diabetic Ketoacidosis. *Chest* 2014; 145(3):161A.
24. Hennings JM, Ising M, Grautoff S, Himmerich H, Pollmächer T, Schaaf L. Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls. *Exp Clin Endocrinol Diabetes* 2010; 118(2):98-100.
25. Fisfalen ME, Hsiung RC. Glucose dysregulation and mirtazapine-induced weight gain. *American Journal of Psychiatry* 2003; 160(4): 797-797.
26. Chen R, Lopes J. Hyperglycaemia secondary to mirtazapine therapy in a 37-year-old man. *The Australian and New Zealand journal of psychiatry* 2008; 42(11):990-991.
27. Li R, Chen LZ, Zhao W, Zhao SP, Huang XS. Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway. *Biochemical and biophysical research communications* 2016; 478(3):1173-1178.
28. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. *Open Cardiovasc Med J* 2011; 5:85-9.
29. Fogari R, Zoppi A, Lazzari P, Mugellini A, Lusardi P, Preti P *et al.* Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. *Journal of human hypertension* 1997; 11(11):753-757.
30. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts A *et al.* A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 1981; 30:239-45.
31. Navarro DM, Shihadeh LA, Plasencia GI. Mirtazapine-associated pancreatitis. *Medicina clinica* 2018; 150(5): 206.

Table I. ADR probability scale

To assess the adverse drug reaction, please answer the following questionnaire and give the pertinent score.

	<i>Yes</i>	<i>No</i>	<i>Do not know</i>	<i>Score</i>
1. Are there previous <i>conclusive</i> reports on this reaction?	+1	0	0	
2. Did the adverse event appear after the suspected drug was administered?	+2	-1	0	
3. Did the adverse reaction improve when the drug was discontinued or a <i>specific</i> antagonist was administered?	+1	0	0	
4. Did the adverse reaction reappear when the drug was readministered?	+2	-1	0	
5. Are there alternative causes (other than the drug) that could on their own have caused the reaction?	-1	+2	0	
6. Did the reaction reappear when a placebo was given?	-1	+1	0	
7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic?	+1	0	0	
8. Was the reaction more severe when the dose was increased, or less severe when the dose was decreased?	+1	0	0	
9. Did the patient have a similar reaction to the same or similar drugs in <i>any</i> previous exposure?	+1	0	0	
10. Was the adverse event confirmed by any objective evidence?	+1	0	0	
			Total score	




Figure 1: Triglyceride values before and after the initiation of mirtazapine.

Figure 1: Serum fasting triglyceride levels before and after the initiation of mirtazapine.




Figure 2: Glucose values before and after the initiation of mirtazapine.

Figure 2: Serum fasting glucose levels before and after the initiation of mirtazapine.